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Profilin is a marker of severity in allergic respiratory diseases 1 
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Background: The capacity of profilin to induce allergic symptoms in patients with 9 
respiratory allergy has been questioned. In that sense, the aim of this study was to 10 
investigate the correlation between profilin exposure and induction of symptoms in a 11 
prospective case-control study. 12 
Methods: The concentration of profilin as well pollen levels were measured. A diary 13 
score of symptoms was collected from allergic patients. Seventy-nine individuals were 14 
included in the study; 51 cases and 28 controls were positive and negative to profilin, 15 
respectively.  16 
Conjunctival and bronchial provocation tests were performed with purified profilin (Pho 17 
d 2) in a subgroup of cases and controls. 18 
Results: Profilin was detected in the environment in 133 days (maximum peak of 0.56 19 
ng/m3). A positive correlation between profilin and pollen count of Olea and Poaceae 20 
was observed. Intensity of total, nasal and ocular symptoms was statistically higher in 21 
cases than in controls (p<0.001). The risk of suffering symptoms was also higher in 22 
cases than in controls. The provocation test was positive in 95% of bronchial and 90% 23 
of conjunctival challenges in cases, and negative in all controls. 24 
Conclusions: Profilin has been detected in the environment and has the ability to induce 25 
a specific allergen response. Patients sensitised to this panallergen showed more 26 
symptoms and are more likely to have symptoms. Therefore, sensitisation to profilin 27 
seems to be a marker of severity in patients with rhinoconjunctivitis and asthma 28 
mediated by pollen. 29 
 30 






Introduction   35 
Profilin is an ubiquitous family of proteins of about 12–16 kDa present in eukaryotic 36 
cells and involved in the control of actin polymerisation1,2. They  have been reported as 37 
panallergens and their similar tertiary structure, even among taxonomically separated 38 
plant species, is the cause of their high cross-reactivity3,4. However, profilins are 39 
considered a minor allergens because their clinical relevance is limited3.  40 
The sensitisation profile of patients is highly variable (20% to 30% of patients with 41 
pollen allergy) and mainly depends on geographical distribution and other concomitant 42 
and predominant allergens5,6. In Central and Northern Europe, profilin sensitisation has 43 
mainly been associated with respiratory allergy to birch7, while in Southern Europe  is 44 
associated with high exposure to grasses, which sensitise up to 60% of patients8. On the 45 
contrary, in some areas of Australia, where ragweed pollen is predominant, 50% of 46 
patients allergic to pollen are sensitised to profilin3. 47 
Apart from the relevance of their sensitisation capacity, profilins have been reported as 48 
a co-factor in pollen allergy. Some authors attribute these percentages to co-recognition, 49 
or cross-reactivity4,9,10. On the contrary, some authors are recently questioning the lack 50 
of relevance of profilin recognized so far11,12. Recent studies have revealed that early 51 
sensitisation to profilin could be an early marker of predisposition to more severe 52 
allergic disease13. The presence of profilin-specific IgE has been associated with an 53 
increased risk of sensitisation to multiple pollens and the presence of food allergy14 and 54 
higher risk of allergic reactions to specific immunotherapy15. 55 
With the aim of investigating the capacity of profilin to induce allergic symptoms in 56 
patients residing in our area of influence, the objective of this study was to measure the 57 
concentration of profilin in the environment and to establish a correlation between 58 
clinical symptoms and profilin exposure by challenging our population to a conjunctival 59 
and bronchial provocation test with purified profilin, in a prospective case-control 60 
study. 61 
 62 
Materials and methods 63 
Patient population 64 
This study consists of a case-control study. The patient population consisted on patients 65 
older than 14 years who came to the Hospital Universitario Infanta Elena (Valdemoro, 66 
Madrid, Spain) for the first time, due to allergic respiratory pathology (rhinitis, 67 
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rhinoconjunctivitis and/or asthma). Over one year, all patients completed symptom 68 
diary cards.  69 
All patients gave written consent to participate in the study. Individuals with severe 70 
atopic dermatitis, uncontrolled bronchial asthma or any other severe respiratory 71 
pathology that limits performing diagnostic tests and evaluation of the results thereof, or 72 
who declined consent, were excluded from the study.  73 
The study protocol was approved by the Clinical Research Ethics Committee of the 74 
Jiménez Díaz Foundation (Madrid, Spain) (Number EO172011FJD). 75 
Cases consisted of patients with rhinitis, rhinoconjunctivitis and/or asthma and 76 
sensitized to profilin while the control group included patients with rhinitis, 77 
rhinoconjunctivitis and/or asthma but negative to profilin. Serum samples from patients 78 
were collected for further studies. 79 
 80 
In vivo Studies 81 
Skin prick tests 82 
All individuals recruited were skin prick tested (SPT) with a standard battery of 83 
biologically standardized aeroallergens including mixture of grasses, Lolium perenne, 84 
Secale cereale, Cynodon dactylon, Olea europaea, Cupressus arizonica, Platanus 85 
hybrida, Parietaria judaica, Salsola kali, moulds (Alternaria alternata), mites 86 
(Dermatophagoides pteronyssinus and Dermatophagoides farinae) and animal epithelia 87 
(cat and dog), fruits including peach (peel and pulp), apple, plum, orange, melon, kiwi, 88 
banana, avocado, and fig and latex (LETIPharma, Madrid, Spain) and with purified 89 
profilin (produced under GMP conditions) from Phoenix dactylifera (Pho d 2, 50 90 
µg/mL16) (LETIPharma). 91 
Conjunctival allergen challenge 92 
Conjunctival challenges were performed according to the usual technique17 with 93 
purified Pho d 2 in 5 concentrations increasing from 0.003 μg/mL to 3 μg/mL dissolved 94 
in saline solution (0.85% NaCl, phosphate buffer 7 mM), following the recently 95 
recommended evaluation criteria18. Conjunctival challenges were performed in 10 cases 96 
and 5 controls outside the symptom registration period so as not to interfere with the 97 
symptom diary card.  98 
Bronchial challenge 99 
Specific bronchial challenge tests were performed with purified profilin16 in serial 100 
dilutions in sterile PBS (phosphate-buffered saline) by the tidal flow method doubling 101 
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concentrations of the antigen dissolved in sterile PBS from 0.15 µg/mL to 30 µg/mL, 102 
according to the previously reported technique19,20. Late response with peak flow was 103 
controlled in the 24 hours after the test. Specific bronchial challenge tests were 104 
performed in 20 cases and 10 controls outside the symptom registration period in diary 105 
card. 106 
 107 
In vitro studies 108 
sIgE and immunoblotting 109 
Specific IgE (sIgE) to rPhl p 12 and rBet v 2 was determined (ImmunoCap, Thermo 110 
Fisher, Uppsala, Sweden). 111 
In addition, recognition of Pho d 2 by the patients’ sera was analysed by immunoblot as 112 
reported16.  113 
 114 
Aerobiological and clinical studies  115 
Air sampling 116 
A volumetric air sampler (Air Sentinel, Quan-Tec-Air Inc., Rochester, Minnesota, 117 
USA) adapted for outdoor use21 was used for aeroallergen collection. The collector was 118 
run continuously during 2012. The sampler was placed 8.26 m above street level in 119 
Valdemoro (coordinates 40°11′53″N 3°41′50″O). Air flow was 10 m3/h. Airborne 120 
particles were collected onto polytetrafluoroethylene membranes (Merck Millipore, 121 
Tullagreen, Ireland). Sampling time for each filter was 24 hours, which represents 240 122 
m3 of air per sample. Filters were replaced at approximately the same time each day. 123 
After removal, filters were sealed in plastic bags and stored at 4°C until extraction. 124 
Filter Extraction and Allergen Quantification 125 
The upper layer of 220 filters was separated and individually placed in tubes containing 126 
2 mL of 0.01M PBS. Tubes were stirred until the filter was completely soaked and left 127 
for overnight extraction in a rotary mixer at 4°C. Afterwards, the content was collected 128 
and the filter discarded.  129 
Allergen content was measured by ELISA inhibition22. In short, purified Pho d 2 was 130 
used as standard (from 1.95 ng to 1000 ng). Microplates were coated with profilin at 131 
1µg/well. Samples were incubated with polyclonal anti-Pho d 2 antibodies produced in 132 
rabbit as previously reported16 (dilution 1:30000). Allergen concentrations were 133 
extrapolated using the standard curve and were based on inhibition capacity; final 134 
results were expressed in ng/m3 of air. 135 
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Pollen count 136 
Aerobiological sampling was performed from January 1st to 31st December, 2012 with a 137 
Burkard pollen collector (Hertfordshire, UK) placed in Valdemoro one metre from the 138 
volumetric air sampler. Samples were examined under optic microscope with a 100X 139 
objective lens. Pollen concentrations were expressed as pollen grains/m3 of air. 140 
Symptom Diary Cards 141 
Throughout the year, all the patients were given diary cards on which they recorded 142 
their conjunctival, nasal, and bronchial symptom scores according to the following 143 
scale22,23: 0, no symptoms; 1, mild symptoms (slight nasal obstruction, slightly runny 144 
nose, or occasional sneezing or itching of the eyes); 2, moderate symptoms (moderate 145 
nasal obstruction, moderately runny nose, some sneezing and congestion, some ocular 146 
itching, or mild asthma); 3, severe symptoms (complete nasal obstruction, almost 147 
continuously runny nose, frequent sneezing or ocular symptoms or asthma attacks).  148 
 149 
Statistical analysis 150 
The chi-square test (χ2) was used to study the relationship between study variables. The 151 
Mann-Whitney Rank Sum Test was used to compare numerical numbers obtained for 152 
the different groups. Linear regression and logistic regression models were used to 153 
evaluate the relationship of variables to the intensity and presence of symptoms, 154 
respectively. Scatter plots were used and the Spearman correlation coefficient was 155 
calculated to evaluate IgE concentration and symptom severity. The software GraphPad 156 
Prims 7 (La Jolla, CA, USA) and OpenEpi ( http://www.openepi.com ) were used for 157 
analyses.  158 
 159 
Results 160 
Patient population 161 
Seventy-nine patients (mean age 30.1±8.5 years), were included in the study: 51 162 
positive to profilin (cases) and 28 negative to profilin (controls). The characteristics of 163 
the population are shown in Table 1. 164 
Cases had statistically more food allergy symptoms than controls (80.4% vs 14.3%) 165 
(p<0.001). The main symptoms were oral allergy syndrome and the main fruit involved 166 
in symptoms was melon (p<0.001), as reported by patients (68.6% vs 7.1%), and 167 




In vivo studies (profilin diagnosis) 170 
SPT 171 
Mean value for wheal sizes induced by profilin in the 51 cases was 32.9±23.1 mm2. 172 
A total of 86.3% of cases presented sensitization to 3 or more pollen and only 46.4% of 173 
controls (p=0.04). Most profilin sensitized patients were sensitized to Cynodon dactylon 174 
(92.2%), with statistically significant differences in comparison with profilin negative 175 
patients (53.6%) (p<0.001). There was also a statistically significant correlation 176 
between sensitization to profilin and to Platanus acerifolia (76.5% vs 17.9%) (p<0.001) 177 
and Parietaria judaica (21.6% vs 3.6%) (p<0.05).  178 
Conjunctival challenges 179 
Conjunctival challenges were performed in 15 patients, who gave their consent for the 180 
test 10 cases and 5 controls, being positive in 9 of the 10 cases. The median 181 
concentration that induced the reaction was 0.3 µg/mL. All 5 controls had a negative 182 
challenge test. 183 
Bronchial challenges 184 
Among patients diagnosed with asthma, bronchial challenge with purified Pho d 2 was 185 
performed on the first 20 cases and 10 controls who gave their consent for the test 186 
(Table 2). Nineteen cases (95%) had a positive bronchial challenge with profilin, with 187 
amounts ranging from 0.31 to 20 µg/ml, the mean PC20 being 10.55 µg/mL (SD:11.87). 188 
A statistically significant difference was observed (P<0.001), both in the final FEV1 189 
and in the percentage FEV1 decrease from baseline when comparing cases and controls. 190 
FEV1 decreased a mean of 24.3% for cases and 5.9% for controls. A total of 60% of 191 
cases presented additional symptoms during the test; the most common were nasal 192 
symptoms (35%), cough (20%), and palatal pruritus (20%). There was no late response 193 
in peak flow records during the 24 hours after the test. 194 
All controls had negative bronchial challenge with purified profilin. 195 
 196 
In vitro studies (sIgE and immunoblot) 197 
Serum samples were positive to rPhl p 12 in 38 cases (74.5%) and rBet v 2 in 42 198 
(82.3%) (Figure 1). Values of sIgE were 4.8±10 kU/L in the case of rPhl p 12 and 199 
6.2±10.8 kU/L for rBet v 2. Both profilins were negative in controls. 200 
Immunoblot was performed with all sera. Forty-two of the 51 sera from cases (82.4%) 201 
showed a band of 14 kDa corresponding to Pho d 2 (1) (Figure 1). Sera that did not 202 
recognise Pho d 2 were also negative to rPhl p 12 and rBet v 2 by CAP. None of the 203 
7 
 
controls recognised the profilin in the immunoblots (data not shown). The median total 204 
IgE of patients sensitised to profilin was 264 KU/L, which was significantly higher than 205 
that for controls (91 KU/L), P=0.002. 206 
 207 
Aerobiological and clinical studies 208 
Profilin quantification on filters 209 
A total of 220 filters were analysed. The maximum value was obtained on 10 June with 210 
133.4 ng of profilin in the filter (0.56 ng/m3 of air). The distribution of profilin during 211 
the year is shown in Figure 2. Profilin was detected in the environment in 133 days 212 
(36.5% of the year). For 58 days (15.9% of the year), profilin concentrations higher 213 
than 10 ng were observed in the filters (>0.04 ng/m3 of air). The month with the highest 214 
profilin content was June, but there were also other smaller peaks in April and the end 215 
of July (Figure 2).   216 
Correlation of amount of profilin with the pollen count of different species 217 
Plants with pollen counts during the whole year higher than 1000 pollen grains/m3 of air 218 
were: Cupressaceae (2195 pollen grains/m3), Olea (2917), Pinaceae (1994), Platanus 219 
(1072), Poaceae (2504), and Quercus (12747). Others less abundant were 220 
Amaranthaceae, Plantago and Fraxinus. The profilin peak appeared some days after the 221 
pollen peak of Olea and Poaceae (Figure 2). 222 
Patient symptoms diary 223 
Total (Figure 3A), bronchial (Figure 3B), nasal (Figure 3C) and conjunctival (Figure 224 
3D) symptoms were compared between cases and controls.  225 
It was observed that mean intensity of total symptoms, along the year, was on average 226 
0.56 points higher in cases than in controls, 95% CI (0.43,0.70) p<0.001 (Figure 3A); 227 
nasal symptoms 0.26 points higher in cases than in controls, CI (0.18,0.34) p<0.001 228 
(Figure 3C); and conjunctival symptoms 0.27 points higher in cases than in controls, CI 229 
(0.23,0.31) p<0.001 (Figure 3D).  230 
For bronchial symptoms, statistically significant differences (p=0.020) between cases 231 
and controls were limited to the presence of profilin (from March to September) in the 232 
environment (0.10 points; CI (0.02, 0.19) (Figure 3B).  233 
The risk of suffering asthma was higher in cases than in controls with OR 1.32 95% CI 234 
(1.19, 1.46) (p<0.001). The same occurred with nasal and conjunctival symptoms, with 235 
an OR of 1.15 95% CI (1.08, 1.23) (p<0.001) and OR of 1.62 95%CI (1.47, 1.79) 236 
(p<0.001), respectively.  237 
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No correlation was detected between the intensity of these symptoms and sIgE levels to 238 
rPhl p 12 and rBet v 2. 239 
 240 
Discussion   241 
The ubiquitous presence of profilin makes it one of the most studied allergens. In this 242 
study profilin has been quantified in the environment and it has been related to the 243 
clinical symptoms of patients with allergy to pollen. In addition, the capacity of profilin 244 
to induce allergic symptoms has been proven, as this is the first time its capacity in the 245 
real life of patients has been analysed. 246 
In the last few years identification of allergens in the environment has become 247 
important for allergic control of diseases and to establish a relationship with clinical 248 
symptoms22,24,25. According to our knowledge, previously only on one study the 249 
presence of profilin has been quantified in the environment as aeroallergen26 with Ole e 250 
2. In our study June showed the highest profilin concentration followed by May and 251 
April, using purified palm tree profilin (Pho d 2) as standard. As expected the highest 252 
profilin concentration correlates with the highest peaks of pollen grains in the 253 
environment, specially from grasses and olive trees, but with a few days delay between 254 
the peak of these pollens and profilin peak. In fact, the maximum profilin peak was 14 255 
days after the peak of grasses. This could be because the characteristics of profilin 256 
require certain meteorological conditions to be detected in the environment. In this 257 
sense the profilin peak coincided with low levels of relative humidity and high 258 
temperature (data not shown).  259 
The presence of profilin was not limited to the spring season, different concentrations 260 
were detected outside this period. This is consistent because although there are several 261 
pollens that contain profilin among their proteins, the percentage of relative profilin 262 
they contain is variable. Lolium perenne is the pollen with the highest percentage of 263 
relative profilin content compared to the total protein8 (0.80). For the remaining extracts 264 
the profilin percentage is lower; olive tree (0.10), Betula (0.05), Chenopodium (0.04), 265 
Salsola (0.04) and Plantago (0.01)8. The clinical implications of small amounts of 266 
profilin are unknown but may enhance allergic inflammation27. 267 
Although the methodology for extraction and quantification of profilin in the filters 268 
rendered good results, it appears that more sophisticated methods, especially obtaining a 269 
more accurate concentration, could provide more exact data about allergen 270 
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concentration. However, the results provide a clear picture about profilin distribution 271 
over the year.  272 
Once the presence of profilin in the environment was demonstrated, it was necessary to 273 
establish its allergenic relevance and capacity to induce allergic symptoms. Different 274 
techniques to measure sIgE to different profilins gave similar results, suggesting an 275 
appropriate selection of patients sensitized to profilin. Skin tests with purified profilin 276 
are a potent tool to select patients sensitized to these allergens. In order to confirm the 277 
skin prick test, serum samples from patients were investigated in depth by measuring 278 
profilin sensitization. All patients positive to rBet v 2 (birch profilin) by ImmunoCAP 279 
recognised Pho d 2 by immunoblot. This study revealed symptoms produced by profilin 280 
in the cases group. The results are in accordance with recently published studies 281 
confirming, the role of Phl p12 (P. pratense profilin) to produce symptoms in vitro by 282 
induction of T-cell response28. 283 
The ability of profilin as a respiratory allergen to produce symptoms in the conjunctival 284 
and respiratory mucosa has been poorly studied. This study is consistent with previous 285 
studies such as Nuñez et al.29, who demonstrated this ability with positive conjunctival 286 
challenge with nPho d 2 in 65% (11/17) of patients sensitized to profilin. Ruiz-García et 287 
al.8 observed that profilin is also capable of producing respiratory symptoms by means 288 
of bronchial challenges with nPho d 2 positive in 77% of sensitised patients. Our study 289 
confirms profilin’s ability to produce an allergen-specific response locally which makes 290 
prior studies consistent and confirms that profilin should be considered as a respiratory 291 
allergen. Results showed that the concentration of profilin required to produce 292 
symptoms is much higher than that presented in the environment. After demonstrating 293 
the presence of profilins in the environment and their capacity to induce allergic 294 
symptoms, we aimed to analyse its capacity in the real life of patients. Until now, there 295 
are only a few published cases of sensitised patients30,31. Therefore, it is necessary to 296 
correlate the concentration of allergen in the environment with the symptoms that our 297 
patients experienced in real life, as other authors have published with other allergens24,32.  298 
Given that we have observed that there is profilin in the environment and that it can 299 
produce specific respiratory symptoms, it is logical to consider that this allergy could 300 
produce a summing effect on the patients' symptoms, capable of increasing their 301 
intensity or triggering symptoms during certain days when the sum of the allergens to 302 
which the patient is sensitised favours the onset of symptoms.  303 
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Recently published studies confirm that asthma-rhinitis multimorbidity is associated 304 
with IgE polysensitisation33. Anto et al.34 proposed a novel allergic phenotype 305 
characterised by polysensitisation and multimorbidity, which is associated with the 306 
frequency, persistence and severity of allergic symptoms. The presence of profilin-307 
specific IgE has been associated with an increased risk of sensitisation to multiple 308 
pollens14. In our study, since it was a real-life study, and most patients were 309 
polysensitised in both groups, we found that patients sensitised to profilin have a 310 
significantly higher intensity of symptoms that those not sensitised to profilin. We also 311 
observed a higher risk of presenting ocular, nasal and bronchial symptoms in a 312 
statistically significant way compared to controls. This corroborates the idea that 313 
profilin can be a marker of the severity of respiratory disease. Recent metabolomic 314 
studies could account for profilin’s capacity to induce local allergic inflammation in 315 
severe phenotypes27,35. Only a small difference in respiratory symptoms was observed 316 
between the two groups in the presence of profilin; although the statistical significance 317 
is very low (p=0.02). Therefore, further studies will be needed to corroborate this 318 
theory.  319 
It has been published that profilin could be a marker of evolution since sensitisation to 320 
profilin usually appears after a longer evolution time of the allergic disease and with a 321 
higher number of sensitisations36. This is consistent with our study where we detected a 322 
statistically significant difference in years of evolution of respiratory symptoms; this is 323 
higher in patients sensitised to profilin. This could mean that longer exposure time to 324 
allergens and longer evolution time of the disease leads to more allergens that the 325 
patients are sensitised to ranging from major to minor allergens, such as profilin. 326 
However, the opposite pattern could be the study by Asero et al.13, who found that 16% 327 
of preschool children were already sensitised to profilin. Therefore, in this sense, 328 
prospective studies are needed to clarify whether profilin can be an early marker of 329 
severity or a marker of disease course. In our study cases had more years of rhinitis 330 
course than controls, but no statistically significant differences were observed. 331 
However, there were statistically significant differences for the years of asthma course, 332 
which was twice for profilin sensitised patients (5.8±4.9 vs 2.9±2.5 years) (p<0.05). 333 
Rhinitis and asthma multimorbidity is common37 and should be considered together. In 334 
our study we observed higher intensity and more frequency of nasal and ocular 335 
symptoms in cases than in controls. Further studies will be necessary to determine 336 
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whether an aetiological approach of this panallergen is possible with immunotherapy, as 337 
has been proposed with other panallergens such as LTP38,39.  338 
In summary, results demonstrate that profilin is present in the environment. This 339 
profilin is able to produce a specific allergen response at respiratory level in patients 340 
sensitised to this allergen and suffering from rhinoconjunctivitis, asthma or both. In 341 
addition, patients sensitised to this panallergen showed more symptoms and are more 342 
likely to have symptoms. Therefore, sensitisation to profilin might be a marker of 343 
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2 (p value) 
n 79 51 (64.6%) 28 (35.4%)  
Age (years±SD) 30.1±8.5 29.3±8.5 31.5±8.7 NS 
Female n (%) 49(62.0%) 33(64.7%) 16/(57.1%) NS 
Respiratory symptoms    
Rhinitis 79 (100%) 51 (100%) 28 (100%) NS 
Years of evolution  
for rhinitis 
8.6±5.1 9.2±4.9 6.9±5.4 NS 
Conjunctivitis 79 (100%) 51 (100%) 28 (100%) NS 
Asthma 60 (75.9%) 38 (74.5%) 22 (78.6%) NS 
Years of evolution 
for asthma 
4.7±4.4 5.8±4.9 2.9±2.5 p< 0.05 
Sensitization to aeroallergens (SPT)   
Mites 24 (30.4%) 15 (29.4%) 9 (32.1%) NS 
Moulds 18 (22.8%) 12 (23.5%) 6 (21.4%) NS 
Epithelia 47 (59.5%) 31 (60.8%) 16 (57.1%) NS 
Pollen 79 (100%) 51 (100%) 28 (100%) NS 
Cynodon dactylon 62 (78.5%) 47 (92.2%) 15 (53.6%) p< 0.001 
Platanus acerifolia 44 (55.7%) 39 (76.5%) 5 (17.9%) p< 0.001 
Parietaria judaica 12 (15.2%) 11 (21.6%) 1 (3.6%) p< 0.05 
Sensitization to 3 
or more pollen 
50 (73.4 %) 44 (86.3%) 13 (46.4%) p< 0.05 
Food allergy symptoms  
Total 45 (57.0%) 41 (80.4%) 4 (14.3%) p<0.001 
OAS 40 (50.6%) 38 (74.5%) 2 (7.1%) p<0.001 
Anaphylaxis 9 (11.4%) 6 (11.8%) 3 (10.7%) NS 
Involved foods (reported by patients) 
Melon 37 (46.8%) 35 (68.6%) 2 (7.1%) p<0.001 
Watermelon 20 (25.3%) 20 (39.2%) 0 (0%) p<0.001 
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Rosaceae fruits 13 (16.5%) 13 (25.5%) 0 (0%) p<0.05 
Involved foods (SPT) 
Melon 28 (35.4%) 27 (52.9%) 1 (3.6%) p<0.001 
Watermelon 2 (2.5%)  2 (3.9%) 0 (0%) NS 
Rosaceae fruits 11 (13.9%) 8 (15.7%) 3 (10.7%) NS 
Percentages calculated from the “n” in each group.  465 
NS: non-significant. 466 
  467 
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Case-2 3.38 3.51 2.62 25.4 5.00 7.48 Pos 
Case-3 1.87 1.78 1.27 28.7 5.00 6.33 Pos 
Case-12 3.00 3.01 2.35 21.0 10.00 18.67 Pos 
Case-13 3.14 3.02 2.17 28.1 5.00 7.32 Pos 
Case-15 2.62 2.59 2.44 5.8 20.00  Neg 
Case-16 2.64 2.31 1.67 27.7 2.50 3.24 Pos 
Case-17 2.35 2.34 1.84 21.4 0.31 0.43 Pos 
Case-21 2.86 2.9 2.09 28.0 10.00 12.86 Pos 
Case-22 2.94 2.99 2.26 24.4 1.21 1.46 Pos 
Case-24 3.14 3.19 2.55 20.1 20.00 39.36 Pos 
Case-26 4.25 4.33 3.46 20.0 10.00 19.77 Pos 
Case-27 3.02 3.07 2.16 29.7 20.00 26.96 Pos 
Case-31 4.15 4.07 3.13 23.1 2.50 2.98 Pos 
Case-32 3.35 3.36 2.44 27.4 2.50 3.45 Pos 
Case-33 3.17 3.02 1.94 35.8 1.25 1.27 Pos 
Case-34 2.38 2.27 1.75 26.5 2.50 3.96 Pos 
Case-35 4.14 4.11 3.22 21.7 20.00 34.99 Pos 
Case-38 2.61 2.55 2.00 21.6 1.25 2.13 Pos 
Case-48 3.25 3.21 2.44 24.0 1.25 1.19 Pos 







































Control-03 3.12 3.04 2.87 5.6 20 39.83 Neg 
Control-04 3.66 3.70 3.43 7.3 20 39.83 Neg 
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Control-08 3.88 3.71 3.71 0.0 20 39.83 Neg 
Control-11 2.69 2.79 2.80 0.3 20 39.83 Neg 
Control-12 3.46 3.39 3.27 5.4 20 39.83 Neg 
Control-13 4.07 4.11 3.83 7.8 20 39.83 Neg 
Control-15 2.59 2.51 2.50 0.4 20 39.83 Neg 
Control-23 3.78 3.80 3.32 12.2 20 39.83 Neg 
Control-25 2.78 2.52 2.34 7.2 20 39.83 Neg 











   
Pos=Positive result, Neg=Negative result. 469 
Figure Legends 470 
  471 
Figure 1: Immunoblots with the individual serum samples. Two micrograms of purified 472 
Pho d 2 were run in the solid phase. Patients sera were diluted 1:1.  473 
sIgE to rPhl p 12 and rBet v 2 are shown for each patient and expressed in (kU/L)  474 
 475 
Figure 2: Levels of pollen counts (Olea and Poaceae) and profilin during the period of 476 
the study. The profilin peak appeared after the maximum pollen peak of Olea and 477 
Poaceae. 478 
 479 
Figure 3: Correlation between profilin counts and clinical symptoms (n=51 cases and 480 
n=28 controls) throughout the year. A-Total symptoms (p<0.001); B-Bronchial 481 
symptoms (N.S. along the year); significance limited to the presence of profilin in the 482 
environment (p=0.02); C-Nasal symptoms (p<0.001); and D-Conjunctival symptoms 483 
(p<0.001). 484 
